Eiken Chemical Co., Ltd. · TSE:4549

Eiken Chemical — The 50th Union World Conference on Lung Health 2019

15 slides from Eiken Chemical's conference presentation, Nov 2, 2019

  1. Slide 1: TB-LAMP in Cameroon: Two Years After – Results and Lessons Learned

    TB-LAMP IN CAMEROON TWO YEARS AFTER – RESULTS AND LESSONS LEARNED By DONKENG DONFACK Valerie Flore (PhD) Centre Pasteur du Cameroun ( Mycobacteriology unit, NRL-TB, NTP) THE 50TH UNION WORLD CONFERENCE ON LUNG HEALTH 30 OCTOBER - 2 NOVEMBER 2019. HYDERABAD, INDIA

  2. Slide 2: Context

    CONTEXT  Land area: 475,440 sq km  Population: 24 863 337 inhabitants  254 DTCs (Diagnostic and Treatment Centers): 1 DTC/90 000 inhabitants  Epidémiological regions: 12  Incidence: 194/100000 inhabitants Cameroon map TB DIAGNOSIS BEFORE 2017 Main diagnostic tool for initial diagnosis of Pulmon

  3. Slide 3: How It Changed?

    HOW IT CHANGED? 5 2019: Scaling up of TB- Challenges 4 LAMP in 21 DTCs 2018: Procurement of TB- Procurement of 21 LAMP reagents and HumaLoop T and 45000 tests 3 materials Issues 2018: Validation of Procurement of TB-LAMP materials National TB Programme Training of Laboratory technicians Supervisions

  4. Slide 4: Issues and Challenges: Procurement

    ISSUES AND CHALLENGES PROCUREMENT Issues  Absence of all TB-LAMP materials on the GDF catalogue to facilitate procurement  Partial procurement of materials which were not used  About 10 months of negotiation by Human and Eiken to obtain all TB- LAMP materials available on the GDF catalogue  Addi

  5. Slide 5: Issues and Challenges: Implementation

    ISSUES AND CHALLENGES IMPLEMENTATION Challenges  Installation of the 21 HumaLoop T Issues instruments at 21 sites for initial TB diagnosis  Late availability of funds for the training of laboratory technicians  Organization of DTCs by pools at all the regions for sputum-smear negative  Absence o

  6. Slide 6: Implementation Results

    IMPLEMENTATION RESULTS TB DIAGNOSIS USING TB-LAMP from  21 new TB-LAMP sites selected November 2018 to September 2019 according to their workload 12000 10000 10064  Replacement of microscopy test on the 8000 6000 4539 selected sites by TB-LAMP test for initial 4000 diagnosis of pulmonary TB 1215 1

  7. Slide 7: Implementation Results

    IMPLEMENTATION RESULTS  Organization of Sputum smear-negative specimen transfer from microscopy centers to a TB-LAMP center for further testing (Organization of DTCs by pools)  Use of biker, taxi and travel agencies for samples and transportation and results TB-LAMP performed on sputum smear negat

  8. Slide 8: Implementation Results

    IMPLEMENTATION RESULTS  Tuberculosis active cases finding in prisons  Tuberculosis active cases finding in villages TB diagnosis mass campaign in prisons TB diagnosis mass campaign in three 1400 1285 1200 villages 300 1000 827 241 250 218 800 593 200 600 150 400 243 100 67 200 118 47 32 13 20 8 50

  9. Slide 9: Usefulness of TB-LAMP Test During TB Mass Screening

    USEFULNESS OF TB-LAMP TEST DURING TB MASS SCREENING Tuberculosis active case finding in prisons Tuberculosis active case finding in villages Case 1: Nkondengui in Yaoundé Case 2: Ndokayo village in the East Region  Sputum sample collection time: 03 days  Sputum sample collection time: 02 days  Nu

  10. Slide 10: Lessons Learned

    LESSONS LEARNED  Search for Funding  Installation - Include funds for installation and - Install the HumaLoop T instrument in supervision in application the week following the training of laboratory technicians - Include funds to conduct related activities - Supervise TB-LAMP tests performed by th

  11. Slide 11: New Challenges

    NEW CHALLENGES We cannot completely replace microscopy with TB-LAMP in Cameroon, else the HumaLoop will be underused. Our challenge now is to:  Facilitate access to TB-LAMP test for all TB presumptive cases through sample transportation  Organize more TB screening campaigns in order to increase th

  12. Slide 12: Summary

    SUMMARY o 22135 tests already performed from November 2018 to September 2019 with 3505 positive (15.15% positivity rate) o 1498 sputum smear negative specimens have been transferred for TB- LAMP testing with 198 positive cases. It displayed 13.21% positivity rate o HumaLoop T is robust, adequate for

  13. Slide 13: Recommendations to other countries

    Recommendations to other countries  Use TB-LAMP for initial diagnosis of pulmonary TB  Organize transfer of Sputum smear negative specimens to TB-LAMP analysis to give at all the patient access to molecular test.  During fund search, include a budget line for instrument installation, supervision

  14. Slide 14: Acknowledgment

    ACKNOWLEDGMENT The Ministry of Health of Cameroon through the National Tuberculosis Program (NTP) Centre Pasteur du Cameroun Japanese coorperation Eiken Chemical company HUMAN company

  15. Slide 15: Thanks for your kind attention

    THANKS FOR YOUR KIND ATTENTION

Eiken Chemical — The 50th Union World Conference on Lung Health 2019 on 6ix